Olaparib is associated withsignificant clinical benefit in high-grade ovarian cancers with germlineand/or somatic mutations within the BRCA1/2 genes(Fong et al, 2009; Audeh et al, 2010; Tuttet al, 2010; Gelmon etal, 2011; Ledermann et al,2014; Kaufman et al, 2015;Oza et al, 2015). The gene discussed is BRCA1; the disease is ovarian carcinoma.